It has been shown that interactions of SDF-1a with CXCR4 promote the in vitro survival of AML cells and that treatments with SDF-1a antibodies, neutralizing antibodies against CXCR4, and CXCR4 inhibitors are effective against AML cells. This evidence concerns the gene CXCL12 and acute myeloid leukemia.